000860977 001__ 860977
000860977 005__ 20210130000703.0
000860977 0247_ $$2doi$$a10.1212/WNL.0000000000007037
000860977 0247_ $$2ISSN$$a0028-3878
000860977 0247_ $$2ISSN$$a1526-632X
000860977 0247_ $$2Handle$$a2128/21776
000860977 0247_ $$2pmid$$apmid:30737338
000860977 0247_ $$2WOS$$aWOS:000463252900018
000860977 0247_ $$2altmetric$$aaltmetric:55252827
000860977 037__ $$aFZJ-2019-01610
000860977 082__ $$a610
000860977 1001_ $$0P:(DE-HGF)0$$aSchuepbach, W. M. Michael$$b0
000860977 245__ $$aQuality of life predicts outcome of deep brain stimulation in early Parkinson disease
000860977 260__ $$a[S.l.]$$bOvid$$c2019
000860977 3367_ $$2DRIVER$$aarticle
000860977 3367_ $$2DataCite$$aOutput Types/Journal article
000860977 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1551882178_10751
000860977 3367_ $$2BibTeX$$aARTICLE
000860977 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000860977 3367_ $$00$$2EndNote$$aJournal Article
000860977 520__ $$aObjective To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.Methods We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson’s Disease Rating Scale (UPDRS) (UPDRS-III “off” and “on” medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI.Results PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group.Conclusion Impaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS.
000860977 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000860977 588__ $$aDataset connected to CrossRef
000860977 7001_ $$0P:(DE-HGF)0$$aTonder, Lisa$$b1
000860977 7001_ $$0P:(DE-HGF)0$$aSchnitzler, Alfons$$b2
000860977 7001_ $$0P:(DE-HGF)0$$aKrack, Paul$$b3
000860977 7001_ $$0P:(DE-HGF)0$$aRau, Joern$$b4
000860977 7001_ $$0P:(DE-HGF)0$$aHartmann, Andreas$$b5
000860977 7001_ $$0P:(DE-HGF)0$$aHälbig, Thomas$$b6
000860977 7001_ $$0P:(DE-HGF)0$$aPineau, Fanny$$b7
000860977 7001_ $$0P:(DE-HGF)0$$aFalk, Andrea$$b8
000860977 7001_ $$0P:(DE-HGF)0$$aPaschen, Laura$$b9
000860977 7001_ $$0P:(DE-HGF)0$$aPaschen, Stephen$$b10
000860977 7001_ $$0P:(DE-HGF)0$$aVolkmann, Jens$$b11
000860977 7001_ $$0P:(DE-HGF)0$$aDafsari, Haidar S.$$b12
000860977 7001_ $$0P:(DE-Juel1)131613$$aBarbe, Michael$$b13$$ufzj
000860977 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b14$$ufzj
000860977 7001_ $$0P:(DE-HGF)0$$aKühn, Andrea$$b15
000860977 7001_ $$0P:(DE-HGF)0$$aKupsch, Andreas$$b16
000860977 7001_ $$0P:(DE-HGF)0$$aSchneider, Gerd-H.$$b17
000860977 7001_ $$0P:(DE-HGF)0$$aSeigneuret, Eric$$b18
000860977 7001_ $$0P:(DE-HGF)0$$aFraix, Valerie$$b19
000860977 7001_ $$0P:(DE-HGF)0$$aKistner, Andrea$$b20
000860977 7001_ $$0P:(DE-HGF)0$$aChaynes, P. Patrick$$b21
000860977 7001_ $$0P:(DE-HGF)0$$aOry-Magne, Fabienne$$b22
000860977 7001_ $$0P:(DE-HGF)0$$aBrefel-Courbon, Christine$$b23
000860977 7001_ $$0P:(DE-HGF)0$$aVesper, Jan$$b24
000860977 7001_ $$0P:(DE-HGF)0$$aWojtecki, Lars$$b25
000860977 7001_ $$0P:(DE-HGF)0$$aDerrey, Stéphane$$b26
000860977 7001_ $$0P:(DE-HGF)0$$aMaltête, David$$b27
000860977 7001_ $$0P:(DE-HGF)0$$aDamier, Philippe$$b28
000860977 7001_ $$0P:(DE-HGF)0$$aDerkinderen, Pascal$$b29
000860977 7001_ $$0P:(DE-HGF)0$$aSixel-Döring, Friederike$$b30
000860977 7001_ $$0P:(DE-HGF)0$$aTrenkwalder, Claudia$$b31
000860977 7001_ $$0P:(DE-HGF)0$$aGharabaghi, Alireza$$b32
000860977 7001_ $$0P:(DE-HGF)0$$aWächter, Tobias$$b33
000860977 7001_ $$0P:(DE-HGF)0$$aWeiss, Daniel$$b34
000860977 7001_ $$0P:(DE-HGF)0$$aPinsker, Marcus O.$$b35
000860977 7001_ $$0P:(DE-HGF)0$$aRegis, Jean-Marie$$b36
000860977 7001_ $$0P:(DE-HGF)0$$aWitjas, Tatiana$$b37
000860977 7001_ $$0P:(DE-HGF)0$$aThobois, Stephane$$b38
000860977 7001_ $$0P:(DE-HGF)0$$aMertens, Patrick$$b39
000860977 7001_ $$0P:(DE-HGF)0$$aKnudsen, Karina$$b40
000860977 7001_ $$0P:(DE-HGF)0$$aSchade-Brittinger, Carmen$$b41
000860977 7001_ $$0P:(DE-HGF)0$$aHoueto, Jean-Luc$$b42
000860977 7001_ $$0P:(DE-HGF)0$$aAgid, Yves$$b43
000860977 7001_ $$0P:(DE-HGF)0$$aVidailhet, Marie$$b44
000860977 7001_ $$0P:(DE-HGF)0$$aTimmermann, Lars$$b45
000860977 7001_ $$0P:(DE-HGF)0$$aDeuschl, Günther$$b46$$eCorresponding author
000860977 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000007037$$gp. 10.1212/WNL.0000000000007037 -$$n10$$pe1109$$tNeurology$$v92$$x1526-632X$$y2019
000860977 8564_ $$uhttps://juser.fz-juelich.de/record/860977/files/e1109.full.pdf$$yOpenAccess
000860977 8564_ $$uhttps://juser.fz-juelich.de/record/860977/files/e1109.full.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000860977 909CO $$ooai:juser.fz-juelich.de:860977$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000860977 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131613$$aForschungszentrum Jülich$$b13$$kFZJ
000860977 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b14$$kFZJ
000860977 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000860977 9141_ $$y2019
000860977 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000860977 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000860977 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000860977 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2017
000860977 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROLOGY : 2017
000860977 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000860977 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000860977 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000860977 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000860977 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000860977 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000860977 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000860977 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000860977 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000860977 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000860977 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000860977 920__ $$lyes
000860977 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000860977 980__ $$ajournal
000860977 980__ $$aVDB
000860977 980__ $$aUNRESTRICTED
000860977 980__ $$aI:(DE-Juel1)INM-3-20090406
000860977 9801_ $$aFullTexts